Argenx’s VYVGART Sales Surge 96% to $4B Spurs Artisan Fund Confidence
Artisan Mid Cap Fund highlighted Argenx SE as a top Q4 2025 contributor, noting VYVGART sales nearly doubled year-over-year (+96%) to over $4 billion annualized, driven by patient uptake from a prefilled syringe launch. The fund also noted a mid-stage thyroid eye disease trial discontinuation while Argenx shares closed at $826.25.
1. Artisan Fund’s Quarterly Review
In its Q4 2025 letter, Artisan Mid Cap Fund singled out Argenx SE as one of its top contributors based on franchise characteristics and earnings trajectory. The fund’s classes delivered between -0.44% and -0.35% for the quarter versus -3.70% for the Russell Midcap® Growth Index, underscoring Argenx’s relative strength.
2. VYVGART Sales Performance
VYVGART, Argenx’s first-in-class autoimmune therapy, achieved a 96% year-over-year sales increase, pushing annualized revenues past $4 billion. The growth was primarily fueled by new patient uptake following the launch of a prefilled syringe formulation.
3. Trial Discontinuation and Outlook
Late in the quarter, Argenx discontinued a mid-stage trial for thyroid eye disease due to lack of efficacy, tempering some upside. Despite this, the fund maintains confidence in VYVGART’s potential across more than a dozen ongoing indication studies.